188 related articles for article (PubMed ID: 12182051)
1. [Treatment with L-thyroxine for differentiated thyroid carcinoma].
Łacka K
Wiad Lek; 2001; 54 Suppl 1():368-72. PubMed ID: 12182051
[TBL] [Abstract][Full Text] [Related]
2. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
3. [Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma].
Miyakawa M
Nihon Rinsho; 2007 Nov; 65(11):2073-7. PubMed ID: 18018573
[TBL] [Abstract][Full Text] [Related]
4. [L-thyroxine therapy in differentiated thyroid carcinoma: criteria for evaluation of TSH suppression].
Kowalczyk P; Roskosz J; Jurecka-Tuleja B; Gubała E; Czernik E; Jarzab B
Wiad Lek; 2001; 54(5-6):268-76. PubMed ID: 11556209
[TBL] [Abstract][Full Text] [Related]
5. [Hormonal replacement therapy in women after surgery for thyroid cancer treated with suppressive doses of L-thyroxine].
Jastrzebska H; Gietka-Czernel M; Zgliczyński S
Wiad Lek; 2001; 54 Suppl 1():383-8. PubMed ID: 12182054
[TBL] [Abstract][Full Text] [Related]
6. Thyroid-hormone therapy and thyroid cancer: a reassessment.
Biondi B; Filetti S; Schlumberger M
Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):32-40. PubMed ID: 16929364
[TBL] [Abstract][Full Text] [Related]
7. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Biondi B; Cooper DS
Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
[TBL] [Abstract][Full Text] [Related]
8. Glucose tolerance and lipid profile in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomised controlled trial.
Heemstra KA; Smit JW; Eustatia-Rutten CF; Heijboer AC; Frölich M; Romijn JA; Corssmit EP
Clin Endocrinol (Oxf); 2006 Dec; 65(6):737-44. PubMed ID: 17121524
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial.
Eustatia-Rutten CF; Corssmit EP; Pereira AM; Frölich M; Bax JJ; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Mar; 64(3):284-91. PubMed ID: 16487438
[TBL] [Abstract][Full Text] [Related]
10. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
Francia G; Davì MV; Petroziello A; Sussi PL
Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
[TBL] [Abstract][Full Text] [Related]
11. The usefulness of a sensitive thyrotrophin assay in the fine adjustment of thyroxine therapy following ablation for carcinoma.
de Lange WE; Sluiter WJ; Doorenbos H
Neth J Med; 1989 Aug; 35(1-2):11-7. PubMed ID: 2779691
[TBL] [Abstract][Full Text] [Related]
12. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy.
Taillard V; Sardinoux M; Oudot C; Fesler P; Rugale C; Raingeard I; Renard E; Ribstein J; du Cailar G
Clin Endocrinol (Oxf); 2011 Nov; 75(5):709-14. PubMed ID: 21645022
[TBL] [Abstract][Full Text] [Related]
13. Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
Do Cao C; Wémeau JL
Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S47-52. PubMed ID: 26826483
[TBL] [Abstract][Full Text] [Related]
14. Highly sensitive determination of TSH in the follow-up of TSH-suppressive therapy of patients with differentiated thyroid cancer.
Mann K; Saller B; Mehl U; Hörmann R; Moser E
Nuklearmedizin; 1988 Feb; 27(1):24-8. PubMed ID: 3368333
[TBL] [Abstract][Full Text] [Related]
15. Effects of thyroxine withdrawal in biochemical parameters and cardiac function and structure in patients with differentiated thyroid cancer.
Chrisoulidou A; Pazaitou-Panayiotou K; Kaprara A; Platoyiannis D; Lafaras C; Boudina M; Georgiou E; Drimonitis A; Bischiniotis T; Vainas I
Minerva Endocrinol; 2006 Jun; 31(2):173-8. PubMed ID: 16682940
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of effects of L-thyroxine therapy in differentiated thyroid carcinoma on the cardiovascular system --prospective study].
Matuszewska G; Roskosz J; Włoch J; Jurecka-Tuleja B; Hasse-Lazar K; Kowalczyk P; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():373-7. PubMed ID: 12182052
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.
Mikosch P; Igerc I; Kudlacek S; Woloszczuk W; Gallowitsch HJ; Kresnik E; Stettner H; Grimm G; Lind P; Pietschmann P
Eur J Clin Invest; 2006 Aug; 36(8):566-73. PubMed ID: 16893379
[TBL] [Abstract][Full Text] [Related]
19. Cognitive functions and mood during chronic thyrotropin-suppressive therapy with L-thyroxine in patients with differentiated thyroid carcinoma.
Jaracz J; Kucharska A; Rajewska-Rager A; Lacka K
J Endocrinol Invest; 2012 Sep; 35(8):760-5. PubMed ID: 21986400
[TBL] [Abstract][Full Text] [Related]
20. Effects of recombinant human thyrotropin on heart rate variability and blood pressure in patients on l-thyroxine-suppressive therapy for differentiated thyroid carcinoma.
Murialdo G; Casu M; Cappi C; Patrone V; Repetto E; Copello F; Minuto F; Giusti M
Horm Res; 2005; 64(2):100-6. PubMed ID: 16179790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
